ArticleVaccines2024

Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results.

María Jesús López Fernández et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.